PARP 抑制剂耐药性的机制
Mark J O'Connor1, Josep V Forment2
1Oncology R&D, AstraZeneca, Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge, CB2 0AA, UK. mark.j.oconnor@astrazeneca.com.
Cancer treatment and research
|November 17, 2023
概括
聚基酶 (PARP) 抑制剂是有效的癌症药物,向DNA损伤反应. 然而,了解PARP抑制剂耐药机制对于改善各种癌症患者的治疗结果至关重要.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 聚基聚合酶 (PARP) 抑制剂 (PARPi) 是一种针对DNA损伤反应 (DDR) 的新型药物.
- PARPi被确立为卵巢癌维持治疗的护理标准,并已被批准用于乳腺,胰腺和前列腺癌.
- 对PARPi的临床耐药性正在出现,在癌症治疗中产生了大量未满足的需求.
研究的目的:
- 阐明基底的多种机制 聚 (ADP-ribose) 聚合酶抑制剂耐药性.
- 整合PARPi耐药性的临床前模型和临床观察结果.
主要方法:
- 审查和综合现有文献的Poly ((ADP-ribose) 聚合酶抑制剂耐药性.
- 分析研究耐药性路径的临床前研究数据.
- 检查临床数据,报告患者对PARPi治疗的反应和耐药性.
主要成果:
- 识别多种多样的机制,有助于Poly (ADP-ribose) 聚合酶抑制剂耐药性.
- 这些机制在实验室环境和患者群体中都得到了观察和验证.
- 耐药途径的复杂性需要对治疗进步进行全面的理解.
结论:
- 了解Poly ((ADP-ribose) 聚合酶抑制剂耐药性的多方面的机制至关重要.
- 解决这些抵抗机制是改善癌症治疗的长期疗效和患者结果的关键.
- 为了扩大其临床实用性,对克服PARPi耐药性的进一步研究至关重要.
相关概念视频
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Restarting Stalled Replication Forks
5.8K
DNA replication is initiated at sites containing predefined DNA sequences known as origins of replication. DNA is unwound at these sites by the minichromosome maintenance (MCM) helicase and other factors such as Cdc45 and the associated GINS complex.The unwound single strands are protected by replication protein A (RPA) until DNA polymerase starts synthesizing DNA at the 5’ end of the strand in the same direction as the replication fork. To prevent the replication fork from falling apart,...
5.8K
Long-patch Base Excision Repair
7.0K
Since the discovery of the two BER pathways, there has been a debate about how a cell chooses one pathway over the other and the factors determining this selection. Numerous in vitro experiments have pointed out multiple determinants for the sub-pathway selection. These are:
7.0K
DNA Damage can Stall the Cell Cycle
9.2K
In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
9.2K
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Interactions Between Signaling Pathways
6.3K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.3K


